SCHEMBL1404003

SCHEMBL1404003

CCCN(CC)CCCO

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.43
SMN1; SMN2 Q16637 1/20 0.41
HSD17B10 Q99714 2/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2C9 P11712 1/20 0.40
HPGD P15428 1/20 0.40
MAPK1 P28482 1/20 0.40
HIF1A Q16665 1/20 0.40
LMNA P02545 2/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
TSHR P16473 1/20 0.39
KCNH2 Q12809 3/20 0.35
CHRM2 P08172 1/20 0.35
HTR1A P08908 1/20 0.35
ADRA2A P08913 1/20 0.35
CHRM1 P11229 1/20 0.35
DRD1 P21728 1/20 0.35
SLC6A2 P23975 1/20 0.35
SLC6A4 P31645 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1404043 0.92 SMN1; SMN2 (0.46) ALDH1A1SMN1; SMN2HSD17B10CYP1A2CYP2C9
SCHEMBL465303 0.92 HSD17B10 (0.44) ALDH1A1SMN1; SMN2HSD17B10CYP1A2CYP2C9
SCHEMBL27956502 0.90 LMNA (0.48) ALDH1A1SMN1; SMN2HSD17B10CYP1A2CYP2C9
SCHEMBL865665 0.90 ALDH1A1 (0.50) ALDH1A1SMN1; SMN2HSD17B10CYP1A2CYP2C9
SCHEMBL465473 0.89 ALDH1A1 (0.47) ALDH1A1SMN1; SMN2HSD17B10HIF1ALMNA
SCHEMBL557366 0.89 ALDH1A1 (0.47) ALDH1A1SMN1; SMN2HSD17B10HIF1ALMNA
SCHEMBL3429982 0.86 CYP1A2 (0.52) ALDH1A1SMN1; SMN2HSD17B10CYP1A2CYP2C9
SCHEMBL11713997 0.86 HSD17B10 (0.41) ALDH1A1SMN1; SMN2HSD17B10CYP1A2CYP2C9
SCHEMBL3427325 0.86 HSD17B10 (0.41) ALDH1A1SMN1; SMN2HSD17B10CYP1A2CYP2C9
SCHEMBL5052250 0.86 SMN1; SMN2 (0.43) ALDH1A1SMN1; SMN2HSD17B10CYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1399409-B1 METHOD FOR PRODUCING (METH)ACRYLIC ACID ESTERS BASF SE (DE) 2012-10-31 EP claimed
US-8029752-B2 Approach in controlling DSP scale in bayer process NALCO COMPANY (US) 2011-10-04 US claimed
WO-2010117949-A2 NOVEL APPROACH IN CONTROLLING DSP SCALE IN THE BAYER PROCESS NALCO COMPANY (US) 2010-10-14 WO claimed
US-20100254866-A1 NOVEL APPROACH IN CONTROLLING DSP SCALE IN BAYER PROCESS NALCO COMPANY 2010-10-07 US claimed
CN-100349854-C Method for producing (meth) acrylic acid esters BASF AG (DE) 2007-11-21 CN claimed
US-7268251-B2 Method for producing (meth) acrylic acid esters BASF AKTIENGESELLSCHAFT (DE) 2007-09-11 US claimed
US-7026503-B2 Method for producing (meth)acrylic acid esters BASF AKTIENGESELLSCHAFT (DE) 2006-04-11 US claimed
EP-1399408-B1 METHOD FOR PRODUCING (METH)ACRYLIC ACID ESTERS BASF AG (DE) 2006-03-22 EP claimed
US-10174349-B2 Recombinant cell producing 2-hydroxyisobutyric acid EVONIK ROEHM GMBH (DE) 2019-01-08 US disclosed
EP-2291530-B1 RECOMBINANT CELL PRODUCING 2-HYDROXYISOBUTYRIC ACID EVONIK ROEHM GMBH (DE) 2018-12-26 EP disclosed
US-20180000816-A1 Use of a Heterocyclic Bcl-xL Inhibitor and Related Analogs for Removing Senescent Cells in the Treatment of Eye Diseases and Other Age-Related Conditions UNITY BIOTECHNOLOGY, INC. 2018-01-04 US disclosed
CN-107083352-A Produce the recombinant cell of 2 hydroxy-iso-butyric acids 赢创罗姆有限公司 2017-08-22 CN disclosed
WO-2017032699-A1 METHOD FOR PRODUCING LOW-BOILING (METH)ACRYLIC ACID ESTERS BASF SE (DE) 2017-03-02 WO disclosed
US-20150258068-A1 COMBINATION THERAPIES MEI PHARMA, INC. 2015-09-17 US disclosed
WO-2003099253-A1 PERSONAL CARE COMPOSITIONS WITH HYDROXY AMINE NEUTRALIZED POLYMERS UNILEVER PLC (GB) 2003-12-04 WO disclosed
WO-2003099252-A1 COSMETIC COMPOSITIONS WITH HYDROXY AMINE SALTS OF MALONIC ACID UNILEVER PLC (GB) 2003-12-04 WO disclosed
US-20030224023-A1 Cosmetic compositions with hydroxy amine salts of malonic acid UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. 2003-12-04 US disclosed
EP-0838508-B1 Aqueous ink composition for use in an ink-jet printer SEIKO EPSON CORP (JP) 2001-08-29 EP disclosed
US-5871572-A COLORANT, WATER, A WATER-SOLUBLE ORGANIC SOLVENT, AND PECTIC ACID SEIKO EPSON CORPORATION (JP) 1999-02-16 US disclosed
EP-0838508-A2 Aqueous ink composition for use in an ink-jet printer SEIKO EPSON CORPORATION (JP) 1998-04-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030224023-A1 Cosmetic compositions with hydroxy amine salts of malonic acid CUTA, TYR, DDC ALDH1A1 281/4885SMN1; SMN2 3395/4885HSD17B10 413/4885
US-20180000816-A1 Use of a Heterocyclic Bcl-xL Inhibitor and Related Analogs for Removing Senescent Cells in the Treatment of Eye Diseases and Other Age-Related Conditions BCL2L1, BCL2, BCL2L13 ALDH1A1 3458/4885SMN1; SMN2 2667/4885HSD17B10 4260/4885
US-20150258068-A1 COMBINATION THERAPIES HDAC1, HDAC8, HDAC5 ALDH1A1 701/4885SMN1; SMN2 1378/4885HSD17B10 3147/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.